<s id="wsj_2341.1"> 33
0 	 1 	 (NP\NP)/NP 	 1 	 Earnings for
0 	 10 	 (S[dcl]\NP)/(S[pss]\NP) 	 1 	 Earnings are
0 	 11 	 (S[pss]\NP)/(S[to]\NP) 	 1 	 Earnings believed <XB>
0 	 14 	 S[pt]\NP 	 1 	 Earnings moved <XB>
2 	 1 	 (NP\NP)/NP 	 2 	 most for
2 	 3 	 (NP\NP)/NP 	 1 	 most of
5 	 4 	 NP[nb]/N 	 1 	 nation the
5 	 6 	 (NP[nb]/N)\NP 	 2 	 nation 's
9 	 3 	 (NP\NP)/NP 	 2 	 makers of
9 	 6 	 (NP[nb]/N)\NP 	 1 	 makers 's
9 	 7 	 N/N 	 1 	 makers major
9 	 8 	 N/N 	 1 	 makers pharmaceutical
11 	 10 	 (S[dcl]\NP)/(S[pss]\NP) 	 2 	 believed are
12 	 11 	 (S[pss]\NP)/(S[to]\NP) 	 2 	 to believed
13 	 12 	 (S[to]\NP)/(S[b]\NP) 	 2 	 have to
14 	 13 	 (S[b]\NP)/(S[pt]\NP) 	 2 	 moved have
14 	 15 	 (S\NP)\(S\NP) 	 2 	 moved ahead
14 	 16 	 (S\NP)\(S\NP) 	 2 	 moved briskly
14 	 17 	 ((S\NP)\(S\NP))/NP 	 2 	 moved in
14 	 22 	 ((S\NP)\(S\NP))/S[dcl] 	 2 	 moved as
20 	 17 	 ((S\NP)\(S\NP))/NP 	 3 	 quarter in
20 	 18 	 NP[nb]/N 	 1 	 quarter the
20 	 19 	 N/N 	 1 	 quarter third
23 	 24 	 (NP\NP)/NP 	 1 	 companies with
23 	 30 	 S[dcl]\NP 	 1 	 companies fared
29 	 24 	 (NP\NP)/NP 	 2 	 drugs with
29 	 25 	 N/N 	 1 	 drugs newer
29 	 27 	 N/N 	 1 	 drugs big-selling
29 	 28 	 N/N 	 1 	 drugs prescription
30 	 22 	 ((S\NP)\(S\NP))/S[dcl] 	 3 	 fared as
30 	 32 	 (S\NP)\(S\NP) 	 2 	 fared well
32 	 31 	 ((S\NP)\(S\NP))/((S\NP)\(S\NP)) 	 3 	 well especially
<\s>
<s id="wsj_2341.2"> 28
4 	 0 	 (S/S)/NP 	 2 	 quarter For
4 	 1 	 NP[nb]/N 	 1 	 quarter the
4 	 2 	 N/N 	 1 	 quarter third
4 	 3 	 N/N 	 1 	 quarter consecutive
8 	 9 	 (NP\NP)/NP 	 1 	 most of
8 	 14 	 (S[dcl]\NP)/(S[pss]\NP) 	 1 	 most were
8 	 15 	 S[pss]\NP 	 1 	 most battered <XB>
11 	 10 	 NP[nb]/N 	 1 	 companies the
11 	 12 	 (NP[nb]/N)\NP 	 2 	 companies '
13 	 9 	 (NP\NP)/NP 	 2 	 revenues of
13 	 12 	 (NP[nb]/N)\NP 	 1 	 revenues '
14 	 0 	 (S/S)/NP 	 1 	 were For
14 	 6 	 S/S 	 1 	 were however
15 	 14 	 (S[dcl]\NP)/(S[pss]\NP) 	 2 	 battered were
15 	 16 	 ((S\NP)\(S\NP))/NP 	 2 	 battered by
15 	 20 	 ((S\NP)\(S\NP))/NP 	 2 	 battered as
19 	 16 	 ((S\NP)\(S\NP))/NP 	 3 	 translations by
19 	 17 	 N/N 	 1 	 translations adverse
19 	 18 	 N/N 	 1 	 translations foreign-currency
22 	 20 	 ((S\NP)\(S\NP))/NP 	 3 	 result as
22 	 21 	 NP[nb]/N 	 1 	 result a
22 	 23 	 (NP\NP)/NP 	 1 	 result of
26 	 23 	 (NP\NP)/NP 	 2 	 dollar of
26 	 24 	 NP[nb]/N 	 1 	 dollar the
26 	 25 	 N/N 	 1 	 dollar strong
26 	 27 	 NP\NP 	 1 	 dollar abroad
<\s>
<s id="wsj_2341.3"> 39
0 	 1 	 (S[dcl]\NP)/S[em] 	 1 	 Analysts said
2 	 1 	 (S[dcl]\NP)/S[em] 	 2 	 that said
5 	 3 	 N/N 	 1 	 Co. Merck
5 	 4 	 N/N 	 1 	 Co. &
5 	 24 	 (S[dcl]\NP)/PP 	 1 	 Co. benefited
10 	 7 	 N/N 	 1 	 Co. Eli
10 	 8 	 N/N 	 1 	 Co. Lilly
10 	 9 	 N/N 	 1 	 Co. &
10 	 24 	 (S[dcl]\NP)/PP 	 1 	 Co. benefited
13 	 12 	 N/N 	 1 	 Co. Warner-Lambert
13 	 24 	 (S[dcl]\NP)/PP 	 1 	 Co. benefited
18 	 15 	 NP[nb]/N 	 1 	 unit the
18 	 16 	 N/N 	 1 	 unit Squibb
18 	 17 	 N/N 	 1 	 unit Corp.
18 	 19 	 (NP\NP)/NP 	 1 	 unit of
18 	 24 	 (S[dcl]\NP)/PP 	 1 	 unit benefited
22 	 19 	 (NP\NP)/NP 	 2 	 Co. of
22 	 20 	 N/N 	 1 	 Co. Bristol-Myers
22 	 21 	 N/N 	 1 	 Co. Squibb
24 	 2 	 S[em]/S[dcl] 	 1 	 benefited that
24 	 23 	 (S\NP)/(S\NP) 	 2 	 benefited all
25 	 24 	 (S[dcl]\NP)/PP 	 2 	 from benefited
27 	 25 	 PP/NP 	 1 	 sales from
27 	 26 	 N/N 	 1 	 sales strong
27 	 28 	 (NP\NP)/NP 	 1 	 sales of
30 	 29 	 (N/N)/(N/N) 	 2 	 new relatively
33 	 28 	 (NP\NP)/NP 	 2 	 medicines of
33 	 30 	 N/N 	 1 	 medicines new
33 	 32 	 N/N 	 1 	 medicines higher-priced
33 	 34 	 (NP\NP)/(S[dcl]\NP) 	 1 	 medicines that
33 	 35 	 (S[dcl]\NP)/NP 	 1 	 medicines provide <XB>
35 	 34 	 (NP\NP)/(S[dcl]\NP) 	 2 	 provide that
38 	 35 	 (S[dcl]\NP)/NP 	 2 	 margins provide
38 	 36 	 N/N 	 1 	 margins wide
38 	 37 	 N/N 	 1 	 margins profit
<\s>
<s id="wsj_2341.4"> 30
1 	 0 	 (N/N)/(N/N) 	 2 	 robust Less
2 	 1 	 N/N 	 1 	 earnings robust
2 	 3 	 (NP\NP)/NP 	 1 	 earnings at
2 	 9 	 (S[dcl]\NP)/(S[pss]\NP) 	 1 	 earnings were
2 	 10 	 (S[pss]\NP)/PP 	 1 	 earnings attributed <XB>
5 	 3 	 (NP\NP)/NP 	 2 	 Inc. at
5 	 4 	 N/N 	 1 	 Inc. Pfizer
8 	 3 	 (NP\NP)/NP 	 2 	 Co. at
8 	 7 	 N/N 	 1 	 Co. Upjohn
10 	 9 	 (S[dcl]\NP)/(S[pss]\NP) 	 2 	 attributed were
11 	 10 	 (S[pss]\NP)/PP 	 2 	 to attributed
13 	 12 	 NP[nb]/N 	 1 	 companies those
13 	 14 	 (NP[nb]/N)\NP 	 2 	 companies '
16 	 11 	 PP/NP 	 1 	 products to
16 	 14 	 (NP[nb]/N)\NP 	 1 	 products '
16 	 15 	 N/N 	 1 	 products older
16 	 20 	 ((NP\NP)/(S[dcl]\NP))\(NP/NP) 	 1 	 products which
18 	 19 	 (NP\NP)/NP 	 1 	 many of
18 	 20 	 ((NP\NP)/(S[dcl]\NP))\(NP/NP) 	 3 	 many which
21 	 20 	 ((NP\NP)/(S[dcl]\NP))\(NP/NP) 	 2 	 face which
23 	 21 	 (S[dcl]\NP)/NP 	 2 	 competition face
23 	 22 	 N/N 	 1 	 competition stiffening
23 	 24 	 (NP\NP)/NP 	 1 	 competition from
26 	 24 	 (NP\NP)/NP 	 2 	 drugs from
26 	 25 	 N/N 	 1 	 drugs generic
29 	 24 	 (NP\NP)/NP 	 2 	 medicines from
29 	 28 	 N/N 	 1 	 medicines other
<\s>
<s id="wsj_2341.5"> 41
1 	 0 	 N/N 	 1 	 Riccardo Joseph
1 	 12 	 (S[dcl]\NP)/S[em] 	 1 	 Riccardo said
4 	 3 	 NP[nb]/N 	 1 	 analyst an
4 	 5 	 (NP\NP)/NP 	 1 	 analyst with
4 	 12 	 (S[dcl]\NP)/S[em] 	 1 	 analyst said
10 	 5 	 (NP\NP)/NP 	 2 	 Co. with
10 	 6 	 N/N 	 1 	 Co. Bear
10 	 8 	 N/N 	 1 	 Co. Stearns
10 	 9 	 N/N 	 1 	 Co. &
13 	 12 	 (S[dcl]\NP)/S[em] 	 2 	 that said
18 	 14 	 (S/S)/NP 	 2 	 years over
18 	 15 	 NP[nb]/N 	 1 	 years the
18 	 16 	 N/N 	 1 	 years past
18 	 17 	 N/N 	 1 	 years few
21 	 19 	 N/N 	 1 	 makers most
21 	 20 	 N/N 	 1 	 makers drug
21 	 22 	 (S[dcl]\NP)/(S[pt]\NP) 	 1 	 makers have
21 	 23 	 (S[pt]\NP)/NP 	 1 	 makers shed <XB>
21 	 28 	 (S[pt]\NP)/NP 	 1 	 makers instituted <XU>
22 	 13 	 S[em]/S[dcl] 	 1 	 have that
22 	 14 	 (S/S)/NP 	 1 	 have over
23 	 22 	 (S[dcl]\NP)/(S[pt]\NP) 	 2 	 shed have
26 	 23 	 (S[pt]\NP)/NP 	 2 	 businesses shed
26 	 24 	 NP[nb]/N 	 1 	 businesses their
26 	 25 	 N/N 	 1 	 businesses slow-growing
28 	 22 	 (S[dcl]\NP)/(S[pt]\NP) 	 2 	 instituted have
31 	 28 	 (S[pt]\NP)/NP 	 2 	 savings instituted
31 	 29 	 N/N 	 1 	 savings other
31 	 30 	 N/N 	 1 	 savings cost
31 	 34 	 (NP\NP)/(S[ng]\NP) 	 1 	 savings as
34 	 33 	 (NP\NP)/(NP\NP) 	 2 	 as such
35 	 34 	 (NP\NP)/(S[ng]\NP) 	 2 	 consolidating as
37 	 35 	 (S[ng]\NP)/NP 	 2 	 plants consolidating
37 	 36 	 N/N 	 1 	 plants manufacturing
40 	 35 	 (S[ng]\NP)/NP 	 2 	 staffs consolidating
40 	 39 	 N/N 	 1 	 staffs administrative
<\s>
<s id="wsj_2341.6"> 24
2 	 0 	 (S/S)/NP 	 2 	 result As
2 	 1 	 NP[nb]/N 	 1 	 result a
6 	 4 	 N/N 	 1 	 products major
6 	 5 	 N/N 	 1 	 products new
6 	 7 	 (S[dcl]\NP)/(S[ng]\NP) 	 1 	 products are
6 	 8 	 ((S[ng]\NP)/PP)/NP 	 1 	 products having <XB>
7 	 0 	 (S/S)/NP 	 1 	 are As
7 	 23 	 (S[dcl]\S[dcl])\NP 	 1 	 are said
8 	 7 	 (S[dcl]\NP)/(S[ng]\NP) 	 2 	 having are
10 	 8 	 ((S[ng]\NP)/PP)/NP 	 3 	 impact having
10 	 9 	 N/N 	 1 	 impact significant
13 	 8 	 ((S[ng]\NP)/PP)/NP 	 2 	 on having
13 	 12 	 PP/PP 	 1 	 on even
15 	 13 	 PP/NP 	 1 	 company on
15 	 14 	 NP[nb]/N 	 1 	 company a
15 	 16 	 (NP\NP)/NP 	 1 	 company with
18 	 17 	 (N/N)/(N/N) 	 2 	 large very
19 	 16 	 (NP\NP)/NP 	 2 	 revenues with
19 	 18 	 N/N 	 1 	 revenues large
22 	 21 	 N/N 	 1 	 Riccardo Mr.
22 	 23 	 (S[dcl]\S[dcl])\NP 	 2 	 Riccardo said
<\s>
<s id="wsj_2341.7"> 27
0 	 1 	 (S[dcl]\NP)/S[dcl] 	 1 	 Analysts said
2 	 3 	 (NP\NP)/NP 	 1 	 profit for
2 	 16 	 (S[dcl]\NP)/(S[pss]\NP) 	 1 	 profit is
2 	 17 	 (S[pss]\NP)/(S[to]\NP) 	 1 	 profit estimated <XB>
2 	 20 	 S[pt]\NP 	 1 	 profit climbed <XB>
10 	 3 	 (NP\NP)/NP 	 2 	 makers for
10 	 4 	 NP[nb]/N 	 1 	 makers the
10 	 5 	 N/N 	 1 	 makers dozen <XU>
10 	 7 	 N/N 	 1 	 makers so
10 	 8 	 N/N 	 1 	 makers big
10 	 9 	 N/N 	 1 	 makers drug
10 	 12 	 (NP\NP)/NP 	 1 	 makers as
14 	 12 	 (NP\NP)/NP 	 2 	 group as
14 	 13 	 NP[nb]/N 	 1 	 group a
16 	 1 	 (S[dcl]\NP)/S[dcl] 	 2 	 is said
17 	 16 	 (S[dcl]\NP)/(S[pss]\NP) 	 2 	 estimated is
18 	 17 	 (S[pss]\NP)/(S[to]\NP) 	 2 	 to estimated
19 	 18 	 (S[to]\NP)/(S[b]\NP) 	 2 	 have to
20 	 19 	 (S[b]\NP)/(S[pt]\NP) 	 2 	 climbed have
20 	 23 	 (S\NP)\(S\NP) 	 2 	 climbed %
20 	 26 	 (S\NP)\(S\NP) 	 2 	 climbed % <XU>
23 	 21 	 ((S\NP)\(S\NP))/((S\NP)\(S\NP)) 	 3 	 % between
23 	 22 	 ((S\NP)\(S\NP))/((S\NP)\(S\NP)) 	 3 	 % 11
26 	 21 	 ((S\NP)\(S\NP))/((S\NP)\(S\NP)) 	 3 	 % between
26 	 25 	 ((S\NP)\(S\NP))/((S\NP)\(S\NP)) 	 3 	 % 14
<\s>
<s id="wsj_2341.8"> 35
1 	 2 	 (S[dcl]\NP)/(S[adj]\NP) 	 1 	 that 's
1 	 4 	 S[adj]\NP 	 1 	 that spectacular <XB>
2 	 0 	 (S/S)/S[dcl] 	 2 	 's While
2 	 3 	 (S\NP)\(S\NP) 	 2 	 's not
4 	 2 	 (S[dcl]\NP)/(S[adj]\NP) 	 2 	 spectacular 's
7 	 6 	 N/N 	 1 	 Sweig Neil
7 	 15 	 (S[dcl]\NP)/S[em] 	 1 	 Sweig said
10 	 9 	 NP[nb]/N 	 1 	 analyst an
10 	 11 	 (NP\NP)/NP 	 1 	 analyst with
10 	 15 	 (S[dcl]\NP)/S[em] 	 1 	 analyst said
13 	 11 	 (NP\NP)/NP 	 2 	 Bache with
13 	 12 	 N/N 	 1 	 Bache Prudential
15 	 0 	 (S/S)/S[dcl] 	 1 	 said While
16 	 15 	 (S[dcl]\NP)/S[em] 	 2 	 that said
18 	 17 	 NP[nb]/N 	 1 	 rate the
18 	 19 	 (NP\NP)/NP 	 1 	 rate of
18 	 21 	 (S[dcl]\NP)/(S[b]\NP) 	 1 	 rate will
18 	 22 	 (S[b]\NP)/(S[adj]\NP) 	 1 	 rate look <XB>
18 	 24 	 S[adj]\NP 	 1 	 rate good <XB>
20 	 19 	 (NP\NP)/NP 	 2 	 growth of
21 	 16 	 S[em]/S[dcl] 	 1 	 will that
22 	 21 	 (S[dcl]\NP)/(S[b]\NP) 	 2 	 look will
22 	 30 	 ((S\NP)\(S\NP))/S[dcl] 	 2 	 look if
24 	 22 	 (S[b]\NP)/(S[adj]\NP) 	 2 	 good look
24 	 23 	 (S[adj]\NP)/(S[adj]\NP) 	 2 	 good especially
24 	 25 	 ((S[adj]\NP)\(S[adj]\NP))/(S[pss]\NP) 	 2 	 good as
26 	 25 	 ((S[adj]\NP)\(S[adj]\NP))/(S[pss]\NP) 	 3 	 compared as
27 	 26 	 (S[pss]\NP)/PP 	 2 	 to compared
29 	 27 	 PP/NP 	 1 	 companies to
29 	 28 	 N/N 	 1 	 companies other
32 	 31 	 NP[nb]/N 	 1 	 economy the
32 	 33 	 S[dcl]\NP 	 1 	 economy turns
33 	 30 	 ((S\NP)\(S\NP))/S[dcl] 	 3 	 turns if
33 	 34 	 (S\NP)\(S\NP) 	 2 	 turns downward
<\s>
<s id="wsj_2341.9"> 53
1 	 0 	 N/N 	 1 	 Sweig Mr.
1 	 2 	 (S[dcl]\NP)/S[em] 	 1 	 Sweig estimated
3 	 2 	 (S[dcl]\NP)/S[em] 	 2 	 that estimated
4 	 5 	 (NP[nb]/N)\NP 	 2 	 Merck 's
6 	 5 	 (NP[nb]/N)\NP 	 1 	 profit 's
6 	 7 	 (NP\NP)/NP 	 1 	 profit for
6 	 10 	 S[dcl]\NP 	 1 	 profit rose
6 	 16 	 S[pss]\NP 	 1 	 profit propelled <XB>
9 	 7 	 (NP\NP)/NP 	 2 	 quarter for
9 	 8 	 NP[nb]/N 	 1 	 quarter the
10 	 3 	 S[em]/S[dcl] 	 1 	 rose that
10 	 11 	 ((S\NP)\(S\NP))/NP 	 2 	 rose by
13 	 12 	 (N/N)/(N/N) 	 2 	 22 about
14 	 11 	 ((S\NP)\(S\NP))/NP 	 3 	 % by
14 	 13 	 N/N 	 1 	 % 22
16 	 17 	 ((S\NP)\(S\NP))/NP 	 2 	 propelled by
18 	 17 	 ((S\NP)\(S\NP))/NP 	 3 	 sales by
18 	 19 	 (NP\NP)/NP 	 1 	 sales of
21 	 19 	 (NP\NP)/NP 	 2 	 line-up of
21 	 20 	 NP[nb]/N 	 1 	 line-up its
21 	 22 	 (NP\NP)/NP 	 1 	 line-up of
25 	 22 	 (NP\NP)/NP 	 2 	 drugs of
25 	 23 	 N/N 	 1 	 drugs fast-growing
25 	 24 	 N/N 	 1 	 drugs prescription
25 	 27 	 (NP\NP)/NP 	 1 	 drugs including
30 	 27 	 (NP\NP)/NP 	 2 	 drug including
30 	 28 	 NP[nb]/N 	 1 	 drug its
30 	 29 	 N/N 	 1 	 drug anti-cholesterol
32 	 27 	 (NP\NP)/NP 	 2 	 Mevacor including
38 	 27 	 (NP\NP)/NP 	 2 	 medicine including
38 	 34 	 NP[nb]/N 	 1 	 medicine a
38 	 35 	 N/N 	 1 	 medicine high
38 	 36 	 N/N 	 1 	 medicine blood
38 	 37 	 N/N 	 1 	 medicine pressure
40 	 27 	 (NP\NP)/NP 	 2 	 Vasotec including
42 	 27 	 (NP\NP)/NP 	 2 	 Primaxin including
45 	 27 	 (NP\NP)/NP 	 2 	 antibiotic including
45 	 44 	 NP[nb]/N 	 1 	 antibiotic an
48 	 27 	 (NP\NP)/NP 	 2 	 Pepcid including
52 	 27 	 (NP\NP)/NP 	 2 	 medication including
52 	 50 	 NP[nb]/N 	 1 	 medication an
52 	 51 	 N/N 	 1 	 medication anti-ulcer
<\s>
<s id="wsj_2341.10"> 26
0 	 1 	 S[dcl]\NP 	 1 	 Profit climbed
1 	 3 	 ((S\NP)\(S\NP))/S[dcl] 	 2 	 climbed though
1 	 25 	 (S[dcl]\S[dcl])\NP 	 1 	 climbed said
3 	 2 	 ((S\NP)\(S\NP))/((S\NP)\(S\NP)) 	 3 	 though even
4 	 5 	 (NP[nb]/N)\NP 	 2 	 Merck 's
6 	 5 	 (NP[nb]/N)\NP 	 1 	 sales 's
6 	 7 	 (S[dcl]\NP)/(S[pss]\NP) 	 1 	 sales were
6 	 8 	 S[pss]\NP 	 1 	 sales reduced <XB>
7 	 3 	 ((S\NP)\(S\NP))/S[dcl] 	 3 	 were though
8 	 7 	 (S[dcl]\NP)/(S[pss]\NP) 	 2 	 reduced were
8 	 9 	 ((S\NP)\(S\NP))/NP 	 2 	 reduced by
8 	 15 	 ((S\NP)\(S\NP))/NP 	 2 	 reduced as
10 	 11 	 ((N/N)\(N/N))/(N/N) 	 2 	 one to
12 	 11 	 ((N/N)\(N/N))/(N/N) 	 3 	 three to
14 	 9 	 ((S\NP)\(S\NP))/NP 	 3 	 points by
14 	 10 	 N/N 	 1 	 points one
14 	 13 	 N/N 	 1 	 points percentage
17 	 15 	 ((S\NP)\(S\NP))/NP 	 3 	 result as
17 	 16 	 NP[nb]/N 	 1 	 result a
17 	 18 	 (NP\NP)/NP 	 1 	 result of
21 	 18 	 (NP\NP)/NP 	 2 	 dollar of
21 	 19 	 NP[nb]/N 	 1 	 dollar the
21 	 20 	 N/N 	 1 	 dollar strong
24 	 23 	 N/N 	 1 	 Sweig Mr.
24 	 25 	 (S[dcl]\S[dcl])\NP 	 2 	 Sweig said
<\s>
<s id="wsj_2341.11"> 18
3 	 0 	 (S/S)/NP 	 2 	 quarter In
3 	 1 	 NP[nb]/N 	 1 	 quarter the
3 	 2 	 N/N 	 1 	 quarter third
3 	 4 	 (NP\NP)/NP 	 1 	 quarter of
5 	 4 	 (NP\NP)/NP 	 2 	 1988 of
7 	 8 	 (S[dcl]\NP)/NP 	 1 	 Merck earned
8 	 0 	 (S/S)/NP 	 1 	 earned In
9 	 8 	 (S[dcl]\NP)/NP 	 2 	 $ earned
11 	 9 	 N/N[num] 	 1 	 million $
11 	 10 	 N/N 	 1 	 million 311.8
15 	 8 	 (S[dcl]\NP)/NP 	 2 	 cents earned
15 	 14 	 N/N 	 1 	 cents 79
15 	 16 	 (NP\NP)/N 	 1 	 cents a
17 	 16 	 (NP\NP)/N 	 2 	 share a
<\s>
<s id="wsj_2341.12"> 16
1 	 0 	 (S/S)/NP 	 2 	 Rahway In
3 	 0 	 (S/S)/NP 	 2 	 N.J. In
7 	 5 	 NP[nb]/N 	 1 	 spokesman a
7 	 6 	 N/N 	 1 	 spokesman Merck
7 	 8 	 (S[dcl]\NP)/S[dcl] 	 1 	 spokesman said
8 	 0 	 (S/S)/NP 	 1 	 said In
10 	 9 	 NP[nb]/N 	 1 	 company the
10 	 11 	 (S[dcl]\NP)/(S[b]\NP) 	 1 	 company does
10 	 13 	 (S[b]\NP)/NP 	 1 	 company make <XB>
11 	 8 	 (S[dcl]\NP)/S[dcl] 	 2 	 does said
11 	 12 	 (S\NP)\(S\NP) 	 2 	 does n't
13 	 11 	 (S[dcl]\NP)/(S[b]\NP) 	 2 	 make does
15 	 13 	 (S[b]\NP)/NP 	 2 	 projections make
15 	 14 	 N/N 	 1 	 projections earnings
<\s>
<s id="wsj_2341.13"> 27
1 	 0 	 N/N 	 1 	 Sweig Mr.
1 	 2 	 (S[dcl]\NP)/S[dcl] 	 1 	 Sweig said
3 	 4 	 (S[dcl]\NP)/S[em] 	 1 	 he estimated
4 	 2 	 (S[dcl]\NP)/S[dcl] 	 2 	 estimated said
5 	 4 	 (S[dcl]\NP)/S[em] 	 2 	 that estimated
6 	 7 	 (NP[nb]/N)\NP 	 2 	 Lilly 's
8 	 7 	 (NP[nb]/N)\NP 	 1 	 earnings 's
8 	 9 	 (NP\NP)/NP 	 1 	 earnings for
8 	 12 	 S[dcl]\NP 	 1 	 earnings jumped
11 	 9 	 (NP\NP)/NP 	 2 	 quarter for
11 	 10 	 NP[nb]/N 	 1 	 quarter the
12 	 5 	 S[em]/S[dcl] 	 1 	 jumped that
12 	 15 	 (S\NP)\(S\NP) 	 2 	 jumped %
12 	 18 	 ((S\NP)\(S\NP))/PP 	 2 	 jumped because
14 	 13 	 (((S\NP)\(S\NP))/((S\NP)\(S\NP)))/(((S\NP)\(S\NP))/((S\NP)\(S\NP))) 	 4 	 20 about
15 	 14 	 ((S\NP)\(S\NP))/((S\NP)\(S\NP)) 	 3 	 % 20
18 	 17 	 ((S\NP)\(S\NP))/((S\NP)\(S\NP)) 	 3 	 because largely
19 	 18 	 ((S\NP)\(S\NP))/PP 	 3 	 of because
21 	 19 	 PP/NP 	 1 	 performance of
21 	 20 	 NP[nb]/N 	 1 	 performance the
21 	 22 	 (NP\NP)/NP 	 1 	 performance of
26 	 22 	 (NP\NP)/NP 	 2 	 Prozac of
26 	 23 	 NP[nb]/N 	 1 	 Prozac its
26 	 24 	 N/N 	 1 	 Prozac new
26 	 25 	 N/N 	 1 	 Prozac anti-depressant
<\s>
<s id="wsj_2341.14"> 19
1 	 0 	 NP[nb]/N 	 1 	 drug The
1 	 3 	 S[pss]\NP 	 1 	 drug introduced <XB>
1 	 7 	 (S[dcl]\NP)/(S[pss]\NP) 	 1 	 drug is
1 	 8 	 (S[pss]\NP)/(S[to]\NP) 	 1 	 drug expected <XB>
1 	 10 	 (S[b]\NP)/NP 	 1 	 drug generate <XB>
3 	 5 	 (S\NP)\(S\NP) 	 2 	 introduced year
5 	 4 	 ((S\NP)\(S\NP))/((S\NP)\(S\NP)) 	 3 	 year last
8 	 7 	 (S[dcl]\NP)/(S[pss]\NP) 	 2 	 expected is
9 	 8 	 (S[pss]\NP)/(S[to]\NP) 	 2 	 to expected
10 	 9 	 (S[to]\NP)/(S[b]\NP) 	 2 	 generate to
10 	 17 	 ((S\NP)\(S\NP))/N 	 2 	 generate this
11 	 10 	 (S[b]\NP)/NP 	 2 	 sales generate
11 	 12 	 (NP\NP)/NP 	 1 	 sales of
14 	 12 	 (NP\NP)/NP 	 2 	 $ of
14 	 13 	 N/N 	 1 	 $ about
16 	 14 	 N/N[num] 	 1 	 million $
16 	 15 	 N/N 	 1 	 million 300
18 	 17 	 ((S\NP)\(S\NP))/N 	 3 	 year this
<\s>
<s id="wsj_2341.15"> 13
0 	 1 	 (S[dcl]\NP)/(S[ng]\NP) 	 1 	 It 's
0 	 2 	 (S[ng]\NP)/(S[to]\NP) 	 1 	 It turning <XB>
0 	 5 	 (S[b]\NP)/NP 	 1 	 It be <XB>
1 	 12 	 (S[dcl]\S[dcl])\NP 	 1 	 's said
2 	 1 	 (S[dcl]\NP)/(S[ng]\NP) 	 2 	 turning 's
2 	 3 	 (S\NP)\(S\NP) 	 2 	 turning out
4 	 2 	 (S[ng]\NP)/(S[to]\NP) 	 2 	 to turning
5 	 4 	 (S[to]\NP)/(S[b]\NP) 	 2 	 be to
8 	 5 	 (S[b]\NP)/NP 	 2 	 blockbuster be
8 	 6 	 NP[nb]/N 	 1 	 blockbuster a
8 	 7 	 N/N 	 1 	 blockbuster real
11 	 10 	 N/N 	 1 	 Sweig Mr.
11 	 12 	 (S[dcl]\S[dcl])\NP 	 2 	 Sweig said
<\s>
<s id="wsj_2341.16"> 18
2 	 1 	 N/N 	 1 	 year last
2 	 3 	 (NP[nb]/N)\NP 	 2 	 year 's
5 	 0 	 (S/S)/NP 	 2 	 quarter In
5 	 3 	 (NP[nb]/N)\NP 	 1 	 quarter 's
5 	 4 	 N/N 	 1 	 quarter third
7 	 8 	 (S[dcl]\NP)/NP 	 1 	 Lilly earned
8 	 0 	 (S/S)/NP 	 1 	 earned In
9 	 8 	 (S[dcl]\NP)/NP 	 2 	 $ earned
11 	 9 	 N/N[num] 	 1 	 million $
11 	 10 	 N/N 	 1 	 million 171.4
14 	 8 	 (S[dcl]\NP)/NP 	 2 	 $ earned
14 	 16 	 (NP\NP)/N 	 1 	 $ a
15 	 14 	 N/N[num] 	 1 	 1.20 $
17 	 16 	 (NP\NP)/N 	 2 	 share a
<\s>
<s id="wsj_2341.17"> 6
1 	 0 	 (S/S)/NP 	 2 	 Indianapolis In
3 	 4 	 (S[dcl]\NP)/NP 	 1 	 Lilly declined
4 	 0 	 (S/S)/NP 	 1 	 declined In
5 	 4 	 (S[dcl]\NP)/NP 	 2 	 comment declined
<\s>
<s id="wsj_2341.18"> 35
1 	 0 	 N/N 	 1 	 analysts Several
1 	 2 	 (S[dcl]\NP)/S[dcl] 	 1 	 analysts said
3 	 4 	 ((S[dcl]\NP)/(S[to]\NP))/NP 	 1 	 they expected
4 	 2 	 (S[dcl]\NP)/S[dcl] 	 2 	 expected said
5 	 6 	 (NP[nb]/N)\NP 	 2 	 Warner-Lambert 's
7 	 4 	 ((S[dcl]\NP)/(S[to]\NP))/NP 	 3 	 profit expected
7 	 6 	 (NP[nb]/N)\NP 	 1 	 profit 's
7 	 10 	 S[b]\NP 	 1 	 profit increase <XB>
9 	 4 	 ((S[dcl]\NP)/(S[to]\NP))/NP 	 2 	 to expected
9 	 8 	 (S\NP)/(S\NP) 	 2 	 to also
10 	 9 	 (S[to]\NP)/(S[b]\NP) 	 2 	 increase to
10 	 11 	 ((S\NP)\(S\NP))/NP 	 2 	 increase by
10 	 16 	 ((S\NP)\(S\NP))/NP 	 2 	 increase from
12 	 13 	 ((N/N)/(N/N))\(S[adj]\NP) 	 3 	 more than
14 	 13 	 ((N/N)/(N/N))\(S[adj]\NP) 	 2 	 20 than
15 	 11 	 ((S\NP)\(S\NP))/NP 	 3 	 % by
15 	 14 	 N/N 	 1 	 % 20
17 	 16 	 ((S\NP)\(S\NP))/NP 	 3 	 $ from
17 	 28 	 (S[dcl]\NP)/NP 	 2 	 $ reported <XU>
19 	 17 	 N/N[num] 	 1 	 million $
19 	 18 	 N/N 	 1 	 million 87.7
22 	 16 	 ((S\NP)\(S\NP))/NP 	 3 	 $ from
22 	 24 	 (NP\NP)/N 	 1 	 $ a
22 	 28 	 (S[dcl]\NP)/NP 	 2 	 $ reported <XU>
23 	 22 	 N/N[num] 	 1 	 1.25 $
25 	 24 	 (NP\NP)/N 	 2 	 share a
27 	 28 	 (S[dcl]\NP)/NP 	 1 	 it reported
28 	 29 	 ((S\NP)\(S\NP))/NP 	 2 	 reported in
32 	 29 	 ((S\NP)\(S\NP))/NP 	 3 	 period in
32 	 30 	 NP[nb]/N 	 1 	 period the
32 	 31 	 N/N 	 1 	 period like
32 	 34 	 NP\NP 	 1 	 period year
34 	 33 	 (NP\NP)/(NP\NP) 	 2 	 year last
<\s>
<s id="wsj_2341.19"> 22
1 	 0 	 NP[nb]/N 	 1 	 company The
1 	 2 	 (S[dcl]\NP)/(S[pss]\NP) 	 1 	 company is
1 	 3 	 S[pss]\NP 	 1 	 company praised <XB>
1 	 8 	 (S[ng]\NP)/NP 	 1 	 company lowering <XB>
1 	 15 	 (S[ng]\NP)/NP 	 1 	 company shedding <XU>
3 	 2 	 (S[dcl]\NP)/(S[pss]\NP) 	 2 	 praised is
3 	 4 	 ((S\NP)\(S\NP))/NP 	 2 	 praised by
3 	 6 	 ((S\NP)\(S\NP))/(S[ng]\NP) 	 2 	 praised for
5 	 4 	 ((S\NP)\(S\NP))/NP 	 3 	 analysts by
8 	 6 	 ((S\NP)\(S\NP))/(S[ng]\NP) 	 3 	 lowering for
8 	 7 	 (S\NP)/(S\NP) 	 2 	 lowering sharply
8 	 11 	 ((S\NP)\(S\NP))/NP 	 2 	 lowering in
10 	 8 	 (S[ng]\NP)/NP 	 2 	 costs lowering
10 	 9 	 NP[nb]/N 	 1 	 costs its
13 	 11 	 ((S\NP)\(S\NP))/NP 	 3 	 years in
13 	 12 	 N/N 	 1 	 years recent
15 	 6 	 ((S\NP)\(S\NP))/(S[ng]\NP) 	 3 	 shedding for
17 	 15 	 (S[ng]\NP)/NP 	 2 	 companies shedding
17 	 16 	 N/N 	 1 	 companies numerous
17 	 18 	 (NP\NP)/NP 	 1 	 companies with
21 	 18 	 (NP\NP)/NP 	 2 	 margins with
21 	 19 	 N/N 	 1 	 margins low
21 	 20 	 N/N 	 1 	 margins profit
<\s>
<s id="wsj_2341.20"> 23
1 	 0 	 NP[nb]/N 	 1 	 company The
1 	 2 	 (NP[nb]/N)\NP 	 2 	 company 's
4 	 2 	 (NP[nb]/N)\NP 	 1 	 operation 's
4 	 3 	 N/N 	 1 	 operation lean
4 	 9 	 ((S[dcl]\NP)/(S[to]\NP))/NP 	 1 	 operation allowed
6 	 7 	 (S[dcl]\NP)/S[dcl] 	 1 	 analysts said
11 	 9 	 ((S[dcl]\NP)/(S[to]\NP))/NP 	 3 	 sales allowed
11 	 10 	 N/N 	 1 	 sales sharp-rising
11 	 12 	 (NP\NP)/NP 	 1 	 sales from
11 	 20 	 (S[b]\NP)/NP 	 1 	 sales power <XB>
15 	 12 	 (NP\NP)/NP 	 2 	 drug from
15 	 13 	 NP[nb]/N 	 1 	 drug its
15 	 14 	 N/N 	 1 	 drug cholesterol
17 	 12 	 (NP\NP)/NP 	 2 	 Lopid from
19 	 9 	 ((S[dcl]\NP)/(S[to]\NP))/NP 	 2 	 to allowed
20 	 19 	 (S[to]\NP)/(S[b]\NP) 	 2 	 power to
22 	 20 	 (S[b]\NP)/NP 	 2 	 growth power
22 	 21 	 N/N 	 1 	 growth earnings
<\s>
<s id="wsj_2341.21"> 20
1 	 0 	 N/N 	 1 	 sales Lopid
1 	 2 	 (S[dcl]\NP)/(S[pss]\NP) 	 1 	 sales are
1 	 3 	 (S[pss]\NP)/(S[to]\NP) 	 1 	 sales expected <XB>
1 	 5 	 (S[b]\NP)/NP 	 1 	 sales be <XB>
3 	 2 	 (S[dcl]\NP)/(S[pss]\NP) 	 2 	 expected are
4 	 3 	 (S[pss]\NP)/(S[to]\NP) 	 2 	 to expected
5 	 4 	 (S[to]\NP)/(S[b]\NP) 	 2 	 be to
5 	 10 	 ((S\NP)\(S\NP))/N 	 2 	 be this
5 	 13 	 ((S\NP)\(S\NP))/PP 	 2 	 be up
7 	 5 	 (S[b]\NP)/NP 	 2 	 $ be
7 	 6 	 N/N 	 1 	 $ about
9 	 7 	 N/N[num] 	 1 	 million $
9 	 8 	 N/N 	 1 	 million 300
11 	 10 	 ((S\NP)\(S\NP))/N 	 3 	 year this
14 	 13 	 ((S\NP)\(S\NP))/PP 	 3 	 from up
14 	 18 	 (PP\PP)/NP 	 1 	 from in
15 	 14 	 PP/NP 	 1 	 $ from
17 	 15 	 N/N[num] 	 1 	 million $
17 	 16 	 N/N 	 1 	 million 190
19 	 18 	 (PP\PP)/NP 	 2 	 1988 in
<\s>
<s id="wsj_2341.22"> 20
2 	 0 	 (S/S)/NP 	 2 	 Plains In
2 	 1 	 N/N 	 1 	 Plains Morris
4 	 0 	 (S/S)/NP 	 2 	 N.J. In
7 	 6 	 NP[nb]/N 	 1 	 spokesman a
7 	 8 	 (NP\NP)/NP 	 1 	 spokesman for
7 	 11 	 (S[dcl]\NP)/S[dcl] 	 1 	 spokesman said
10 	 8 	 (NP\NP)/NP 	 2 	 company for
10 	 9 	 NP[nb]/N 	 1 	 company the
11 	 0 	 (S/S)/NP 	 1 	 said In
13 	 12 	 NP[nb]/N 	 1 	 analysts the
13 	 14 	 (NP[nb]/N)\NP 	 2 	 analysts '
15 	 14 	 (NP[nb]/N)\NP 	 1 	 projections '
15 	 16 	 (S[dcl]\NP)/PP 	 1 	 projections are
16 	 11 	 (S[dcl]\NP)/S[dcl] 	 2 	 are said
17 	 16 	 (S[dcl]\NP)/PP 	 2 	 in are
19 	 17 	 PP/NP 	 1 	 ballpark in
19 	 18 	 NP[nb]/N 	 1 	 ballpark the
<\s>
<s id="wsj_2341.23"> 53
0 	 1 	 (NP[nb]/N)\NP 	 2 	 Squibb 's
2 	 1 	 (NP[nb]/N)\NP 	 1 	 profit 's
2 	 4 	 (S[pss]\NP)/(S[to]\NP) 	 1 	 profit estimated <XB>
2 	 8 	 (S[b]\NP)/PP 	 1 	 profit be <XB>
2 	 33 	 (S[dcl]\NP)/NP 	 1 	 profit was
4 	 5 	 ((S\NP)\(S\NP))/NP 	 2 	 estimated by
6 	 5 	 ((S\NP)\(S\NP))/NP 	 3 	 analysts by
7 	 4 	 (S[pss]\NP)/(S[to]\NP) 	 2 	 to estimated
8 	 7 	 (S[to]\NP)/(S[b]\NP) 	 2 	 be to
10 	 9 	 (N/N)/(N/N) 	 2 	 18 about
11 	 10 	 N/N 	 1 	 % 18
11 	 12 	 (PP\NP)/NP 	 1 	 % above
12 	 8 	 (S[b]\NP)/PP 	 2 	 above be
14 	 12 	 (PP\NP)/NP 	 2 	 $ above
14 	 13 	 NP[nb]/N 	 1 	 $ the
14 	 25 	 (S[dcl]\NP)/NP 	 2 	 $ earned <XU>
16 	 14 	 N/N[num] 	 1 	 million $
16 	 15 	 N/N 	 1 	 million 123
19 	 12 	 (PP\NP)/NP 	 2 	 $ above
19 	 21 	 (NP\NP)/N 	 1 	 $ a
19 	 25 	 (S[dcl]\NP)/NP 	 2 	 $ earned <XU>
20 	 19 	 N/N[num] 	 1 	 1.25 $
22 	 21 	 (NP\NP)/N 	 2 	 share a
24 	 25 	 (S[dcl]\NP)/NP 	 1 	 it earned
25 	 26 	 ((S\NP)\(S\NP))/NP 	 2 	 earned in
29 	 26 	 ((S\NP)\(S\NP))/NP 	 3 	 quarter in
29 	 27 	 NP[nb]/N 	 1 	 quarter the
29 	 28 	 N/N 	 1 	 quarter third
29 	 30 	 (NP\NP)/NP 	 1 	 quarter of
31 	 30 	 (NP\NP)/NP 	 2 	 1988 of
35 	 33 	 (S[dcl]\NP)/NP 	 2 	 result was
35 	 34 	 NP[nb]/N 	 1 	 result the
35 	 36 	 (NP\NP)/NP 	 1 	 result of
38 	 37 	 (N/N)/(N/N) 	 2 	 strong especially
39 	 36 	 (NP\NP)/NP 	 2 	 sales of
39 	 38 	 N/N 	 1 	 sales strong
39 	 40 	 (NP\NP)/NP 	 1 	 sales of
43 	 40 	 (NP\NP)/NP 	 2 	 drug of
43 	 41 	 NP[nb]/N 	 1 	 drug its
43 	 42 	 N/N 	 1 	 drug Capoten
43 	 44 	 (NP\NP)/(S[ng]\NP) 	 1 	 drug for
45 	 44 	 (NP\NP)/(S[ng]\NP) 	 2 	 treating for
48 	 45 	 (S[ng]\NP)/NP 	 2 	 pressure treating
48 	 46 	 N/N 	 1 	 pressure high
48 	 47 	 N/N 	 1 	 pressure blood
52 	 45 	 (S[ng]\NP)/NP 	 2 	 disease treating
52 	 50 	 N/N 	 1 	 disease other
52 	 51 	 N/N 	 1 	 disease heart
<\s>
<s id="wsj_2341.24"> 11
1 	 0 	 NP[nb]/N 	 1 	 company The
1 	 2 	 (S[dcl]\NP)/(S[pss]\NP) 	 1 	 company was
1 	 4 	 (S[pss]\NP)/PP 	 1 	 company merged <XB>
4 	 2 	 (S[dcl]\NP)/(S[pss]\NP) 	 2 	 merged was
4 	 3 	 (S\NP)/(S\NP) 	 2 	 merged officially
4 	 9 	 ((S\NP)\(S\NP))/N 	 2 	 merged this
5 	 4 	 (S[pss]\NP)/PP 	 2 	 with merged
7 	 5 	 PP/NP 	 1 	 Co. with
7 	 6 	 N/N 	 1 	 Co. Bristol-Myers
9 	 8 	 ((S\NP)\(S\NP))/((S\NP)\(S\NP)) 	 3 	 this earlier
10 	 9 	 ((S\NP)\(S\NP))/N 	 3 	 month this
<\s>
<s id="wsj_2341.25"> 4
0 	 1 	 (S[dcl]\NP)/(S[to]\NP) 	 1 	 Bristol-Myers declined
0 	 3 	 S[b]\NP 	 1 	 Bristol-Myers comment <XB>
2 	 1 	 (S[dcl]\NP)/(S[to]\NP) 	 2 	 to declined
3 	 2 	 (S[to]\NP)/(S[b]\NP) 	 2 	 comment to
<\s>
<s id="wsj_2341.26"> 40
1 	 0 	 N/N 	 1 	 Riccardo Mr.
1 	 2 	 (NP\NP)/NP 	 1 	 Riccardo of
1 	 5 	 (S[dcl]\NP)/S[em] 	 1 	 Riccardo said
4 	 2 	 (NP\NP)/NP 	 2 	 Stearns of
4 	 3 	 N/N 	 1 	 Stearns Bear
6 	 5 	 (S[dcl]\NP)/S[em] 	 2 	 that said
8 	 7 	 N/N 	 1 	 Corp. Schering-Plough
8 	 9 	 (NP[nb]/N)\NP 	 2 	 Corp. 's
12 	 9 	 (NP[nb]/N)\NP 	 1 	 rise 's
12 	 10 	 N/N 	 1 	 rise expected
12 	 11 	 N/N 	 1 	 rise profit
12 	 13 	 (NP\NP)/NP 	 1 	 rise of
12 	 31 	 (S[dcl]\NP)/S 	 1 	 rise are
16 	 13 	 (NP\NP)/NP 	 2 	 % of
16 	 14 	 N/N 	 1 	 % about
16 	 15 	 N/N 	 1 	 % 18
16 	 17 	 (N\N)/N 	 1 	 % to
19 	 17 	 (N\N)/N 	 2 	 % to
19 	 18 	 N/N 	 1 	 % 20
22 	 23 	 (NP[nb]/N)\NP 	 2 	 Bristol-Meyers 's
26 	 23 	 (NP[nb]/N)\NP 	 1 	 increase 's
26 	 24 	 N/N 	 1 	 increase expected
26 	 25 	 N/N 	 1 	 increase profit
26 	 27 	 (NP\NP)/NP 	 1 	 increase of
26 	 31 	 (S[dcl]\NP)/S 	 1 	 increase are
29 	 28 	 (N/N)/(N/N) 	 2 	 13 about
30 	 27 	 (NP\NP)/NP 	 2 	 % of
30 	 29 	 N/N 	 1 	 % 13
31 	 6 	 S[em]/S[dcl] 	 1 	 are that
33 	 31 	 (S[dcl]\NP)/S 	 2 	 because are
33 	 32 	 S/S 	 1 	 because largely
35 	 34 	 NP[nb]/N 	 1 	 companies those
35 	 36 	 (S[dcl]\NP)/(S[pss]\NP) 	 1 	 companies are
35 	 38 	 S[pss]\NP 	 1 	 companies managed <XB>
36 	 33 	 S/S[dcl] 	 1 	 are because
36 	 37 	 (S\NP)\(S\NP) 	 2 	 are really
38 	 36 	 (S[dcl]\NP)/(S[pss]\NP) 	 2 	 managed are
38 	 39 	 (S\NP)\(S\NP) 	 2 	 managed well
<\s>
<s id="wsj_2341.27"> 32
0 	 1 	 (S[dcl]\NP)/NP 	 1 	 ScheringPlough earned
1 	 12 	 ((S\NP)\(S\NP))/S[dcl] 	 2 	 earned while
2 	 1 	 (S[dcl]\NP)/NP 	 2 	 $ earned
4 	 2 	 N/N[num] 	 1 	 million $
4 	 3 	 N/N 	 1 	 million 94.4
8 	 1 	 (S[dcl]\NP)/NP 	 2 	 cents earned
8 	 7 	 N/N 	 1 	 cents 84
8 	 9 	 (NP\NP)/N 	 1 	 cents a
10 	 9 	 (NP\NP)/N 	 2 	 share a
13 	 14 	 (S[dcl]\NP)/NP 	 1 	 Bristol-Myers earned
14 	 12 	 ((S\NP)\(S\NP))/S[dcl] 	 3 	 earned while
14 	 25 	 ((S\NP)\(S\NP))/NP 	 2 	 earned in
15 	 14 	 (S[dcl]\NP)/NP 	 2 	 $ earned
17 	 15 	 N/N[num] 	 1 	 million $
17 	 16 	 N/N 	 1 	 million 232.3
21 	 14 	 (S[dcl]\NP)/NP 	 2 	 cents earned
21 	 20 	 N/N 	 1 	 cents 81
21 	 22 	 (NP\NP)/N 	 1 	 cents a
23 	 22 	 (NP\NP)/N 	 2 	 share a
28 	 25 	 ((S\NP)\(S\NP))/NP 	 3 	 period in
28 	 26 	 NP[nb]/N 	 1 	 period the
28 	 27 	 N/N 	 1 	 period like
28 	 31 	 (NP\NP)\NP 	 1 	 period earlier
30 	 29 	 NP[nb]/N 	 1 	 year a
30 	 31 	 (NP\NP)\NP 	 2 	 year earlier
<\s>
<s id="wsj_2341.28"> 36
1 	 0 	 (S/S)/NP 	 2 	 Madison In
3 	 0 	 (S/S)/NP 	 2 	 N.J. In
6 	 5 	 NP[nb]/N 	 1 	 spokesman a
6 	 7 	 (NP\NP)/NP 	 1 	 spokesman for
6 	 9 	 (S[dcl]\NP)/S[dcl] 	 1 	 spokesman said
8 	 7 	 (NP\NP)/NP 	 2 	 Schering-Plough for
9 	 0 	 (S/S)/NP 	 1 	 said In
11 	 10 	 NP[nb]/N 	 1 	 company the
11 	 12 	 (S[dcl]\NP)/NP 	 1 	 company has
12 	 9 	 (S[dcl]\NP)/S[dcl] 	 2 	 has said
14 	 12 	 (S[dcl]\NP)/NP 	 2 	 problems has
14 	 13 	 NP[nb]/N 	 1 	 problems no
14 	 15 	 (NP\NP)/NP 	 1 	 problems with
18 	 15 	 (NP\NP)/NP 	 2 	 estimate with
18 	 16 	 NP[nb]/N 	 1 	 estimate the
18 	 17 	 N/N 	 1 	 estimate average
18 	 19 	 (NP\NP)/NP 	 1 	 estimate by
18 	 22 	 (NP\NP)/S[dcl] 	 1 	 estimate that
21 	 19 	 (NP\NP)/NP 	 2 	 analysts by
21 	 20 	 NP[nb]/N 	 1 	 analysts a
24 	 23 	 N/N 	 1 	 earnings third-quarter
24 	 25 	 (NP\NP)/NP 	 1 	 earnings per
24 	 27 	 S[dcl]\NP 	 1 	 earnings rose
26 	 25 	 (NP\NP)/NP 	 2 	 share per
27 	 22 	 (NP\NP)/S[dcl] 	 2 	 rose that
27 	 28 	 ((S\NP)\(S\NP))/NP 	 2 	 rose by
27 	 33 	 ((S\NP)\(S\NP))/NP 	 2 	 rose to
30 	 29 	 (N/N)/(N/N) 	 2 	 19 about
31 	 28 	 ((S\NP)\(S\NP))/NP 	 3 	 % by
31 	 30 	 N/N 	 1 	 % 19
34 	 33 	 ((S\NP)\(S\NP))/NP 	 3 	 $ to
35 	 34 	 N/N[num] 	 1 	 1 $
<\s>
<s id="wsj_2341.29"> 25
1 	 0 	 NP[nb]/N 	 1 	 company The
1 	 2 	 (S[dcl]\NP)/(S[to]\NP) 	 1 	 company expects
1 	 4 	 (S[b]\NP)/NP 	 1 	 company achieve <XB>
2 	 24 	 (S[dcl]\S[dcl])\NP 	 1 	 expects said
3 	 2 	 (S[dcl]\NP)/(S[to]\NP) 	 2 	 to expects
4 	 3 	 (S[to]\NP)/(S[b]\NP) 	 2 	 achieve to
4 	 15 	 ((S\NP)\(S\NP))/S[dcl] 	 2 	 achieve as
7 	 6 	 (N/N)/(N/N) 	 2 	 % 20
8 	 4 	 (S[b]\NP)/NP 	 2 	 increase achieve
8 	 5 	 NP[nb]/N 	 1 	 increase the
8 	 7 	 N/N 	 1 	 increase %
8 	 9 	 (NP\NP)/NP 	 1 	 increase in
8 	 12 	 (NP\NP)/NP 	 1 	 increase per
11 	 9 	 (NP\NP)/NP 	 2 	 earnings in
11 	 10 	 N/N 	 1 	 earnings full-year
13 	 12 	 (NP\NP)/NP 	 2 	 share per
16 	 17 	 S[dcl]\NP 	 1 	 it projected
17 	 15 	 ((S\NP)\(S\NP))/S[dcl] 	 3 	 projected as
17 	 18 	 ((S\NP)\(S\NP))/NP 	 2 	 projected in
20 	 18 	 ((S\NP)\(S\NP))/NP 	 3 	 spring in
20 	 19 	 NP[nb]/N 	 1 	 spring the
23 	 22 	 NP[nb]/N 	 1 	 spokesman the
23 	 24 	 (S[dcl]\S[dcl])\NP 	 2 	 spokesman said
<\s>
<s id="wsj_2341.30"> 27
2 	 3 	 (S[dcl]\NP)/S[dcl] 	 1 	 analysts said
3 	 0 	 S/S 	 1 	 said Meanwhile
4 	 5 	 (NP[nb]/N)\NP 	 2 	 Pfizer 's
7 	 5 	 (NP[nb]/N)\NP 	 1 	 string 's
7 	 6 	 N/N 	 1 	 string recent
7 	 8 	 (NP\NP)/NP 	 1 	 string of
7 	 12 	 S[dcl]\NP 	 1 	 string continued
11 	 8 	 (NP\NP)/NP 	 2 	 performances of
11 	 9 	 N/N 	 1 	 performances lackluster
11 	 10 	 N/N 	 1 	 performances quarterly
12 	 3 	 (S[dcl]\NP)/S[dcl] 	 2 	 continued said
12 	 14 	 ((S\NP)\(S\NP))/S[dcl] 	 2 	 continued as
15 	 16 	 (NP\NP)/NP 	 1 	 earnings in
15 	 19 	 (S[dcl]\NP)/(S[pss]\NP) 	 1 	 earnings were
15 	 20 	 (S[pss]\NP)/(S[to]\NP) 	 1 	 earnings expected <XB>
15 	 22 	 S[b]\NP 	 1 	 earnings decline <XB>
18 	 16 	 (NP\NP)/NP 	 2 	 quarter in
18 	 17 	 NP[nb]/N 	 1 	 quarter the
19 	 14 	 ((S\NP)\(S\NP))/S[dcl] 	 3 	 were as
20 	 19 	 (S[dcl]\NP)/(S[pss]\NP) 	 2 	 expected were
21 	 20 	 (S[pss]\NP)/(S[to]\NP) 	 2 	 to expected
22 	 21 	 (S[to]\NP)/(S[b]\NP) 	 2 	 decline to
22 	 23 	 ((S\NP)\(S\NP))/NP 	 2 	 decline by
25 	 24 	 (N/N)/(N/N) 	 2 	 5 about
26 	 23 	 ((S\NP)\(S\NP))/NP 	 3 	 % by
26 	 25 	 N/N 	 1 	 % 5
<\s>
<s id="wsj_2341.31"> 25
0 	 1 	 (NP\NP)/NP 	 1 	 Sales of
0 	 19 	 (S[dcl]\NP)/(S[pt]\NP) 	 1 	 Sales have
0 	 20 	 S[pt]\NP 	 1 	 Sales shrunk <XB>
2 	 3 	 (NP[nb]/N)\NP 	 2 	 Pfizer 's
5 	 1 	 (NP\NP)/NP 	 2 	 drugs of
5 	 3 	 (NP[nb]/N)\NP 	 1 	 drugs 's
5 	 4 	 N/N 	 1 	 drugs important
7 	 1 	 (NP\NP)/NP 	 2 	 Feldene of
7 	 8 	 (NP\NP)/(S[ng]\NP) 	 1 	 Feldene for
9 	 8 	 (NP\NP)/(S[ng]\NP) 	 2 	 treating for
10 	 9 	 (S[ng]\NP)/NP 	 2 	 arthritis treating
13 	 1 	 (NP\NP)/NP 	 2 	 Procardia of
17 	 1 	 (NP\NP)/NP 	 2 	 medicine of
17 	 15 	 NP[nb]/N 	 1 	 medicine a
17 	 16 	 N/N 	 1 	 medicine heart
20 	 19 	 (S[dcl]\NP)/(S[pt]\NP) 	 2 	 shrunk have
20 	 21 	 ((S\NP)\(S\NP))/PP 	 2 	 shrunk because
22 	 21 	 ((S\NP)\(S\NP))/PP 	 3 	 of because
24 	 22 	 PP/NP 	 1 	 competition of
24 	 23 	 N/N 	 1 	 competition increased
<\s>
<s id="wsj_2341.32"> 15
2 	 1 	 (N/N)/(S[adj]\NP) 	 2 	 strong -LRB-
4 	 0 	 NP[nb]/N 	 1 	 dollar The
4 	 1 	 (N/N)/(S[adj]\NP) 	 1 	 dollar -LRB-
4 	 5 	 (S[dcl]\NP)/NP 	 1 	 dollar hurt
5 	 7 	 ((S\NP)\(S\NP))/N 	 2 	 hurt a
5 	 10 	 (S\NP)\(S\NP) 	 2 	 hurt too
5 	 14 	 (S[dcl]\S[dcl])\NP 	 1 	 hurt said
6 	 5 	 (S[dcl]\NP)/NP 	 2 	 Pfizer hurt
8 	 7 	 ((S\NP)\(S\NP))/N 	 3 	 lot a
13 	 12 	 N/N 	 1 	 Sweig Mr.
13 	 14 	 (S[dcl]\S[dcl])\NP 	 2 	 Sweig said
<\s>
<s id="wsj_2341.33"> 18
3 	 0 	 (S/S)/NP 	 2 	 quarter In
3 	 1 	 NP[nb]/N 	 1 	 quarter the
3 	 2 	 N/N 	 1 	 quarter third
5 	 4 	 (S/S)/(S/S) 	 2 	 year last
7 	 8 	 (S[dcl]\NP)/NP 	 1 	 Pfizer earned
8 	 0 	 (S/S)/NP 	 1 	 earned In
8 	 5 	 S/S 	 1 	 earned year
9 	 8 	 (S[dcl]\NP)/NP 	 2 	 $ earned
11 	 9 	 N/N[num] 	 1 	 million $
11 	 10 	 N/N 	 1 	 million 216.8
14 	 8 	 (S[dcl]\NP)/NP 	 2 	 $ earned
14 	 16 	 (NP\NP)/N 	 1 	 $ a
15 	 14 	 N/N[num] 	 1 	 1.29 $
17 	 16 	 (NP\NP)/N 	 2 	 share a
<\s>
<s id="wsj_2341.34"> 8
2 	 0 	 (S/S)/NP 	 2 	 York In
2 	 1 	 N/N 	 1 	 York New
5 	 4 	 NP[nb]/N 	 1 	 company the
5 	 6 	 (S[dcl]\NP)/NP 	 1 	 company declined
6 	 0 	 (S/S)/NP 	 1 	 declined In
7 	 6 	 (S[dcl]\NP)/NP 	 2 	 comment declined
<\s>
<s id="wsj_2341.35"> 38
0 	 1 	 (S[dcl]\NP)/S[dcl] 	 1 	 Analysts said
2 	 3 	 ((S[dcl]\NP)/(S[to]\NP))/NP 	 1 	 they expected
3 	 1 	 (S[dcl]\NP)/S[dcl] 	 2 	 expected said
4 	 5 	 (NP[nb]/N)\NP 	 2 	 Upjohn 's
6 	 3 	 ((S[dcl]\NP)/(S[to]\NP))/NP 	 3 	 profit expected
6 	 5 	 (NP[nb]/N)\NP 	 1 	 profit 's
6 	 9 	 S[adj]\NP 	 1 	 profit flat <XB>
6 	 11 	 S[b]\NP 	 1 	 profit rise <XU>
7 	 3 	 ((S[dcl]\NP)/(S[to]\NP))/NP 	 2 	 to expected
8 	 7 	 (S[to]\NP)/(S[b]\NP) 	 2 	 be to
9 	 8 	 (S[b]\NP)/(S[adj]\NP) 	 2 	 flat be
11 	 7 	 (S[to]\NP)/(S[b]\NP) 	 2 	 rise to
11 	 12 	 ((S\NP)\(S\NP))/NP 	 2 	 rise by
16 	 12 	 ((S\NP)\(S\NP))/NP 	 3 	 % by
16 	 13 	 N/N 	 1 	 % only
16 	 14 	 N/N 	 1 	 % about
16 	 15 	 N/N 	 1 	 % 2
16 	 17 	 (N\N)/N 	 1 	 % to
16 	 20 	 (NP\NP)/(S[pss]\NP) 	 1 	 % as
16 	 21 	 (S[pss]\NP)/PP 	 1 	 % compared <XB>
19 	 17 	 (N\N)/N 	 2 	 % to
19 	 18 	 N/N 	 1 	 % 4
21 	 20 	 (NP\NP)/(S[pss]\NP) 	 2 	 compared as
22 	 21 	 (S[pss]\NP)/PP 	 2 	 with compared
23 	 22 	 PP/NP 	 1 	 $ with
23 	 34 	 (S[dcl]\NP)/NP 	 2 	 $ earned <XU>
25 	 23 	 N/N[num] 	 1 	 million $
25 	 24 	 N/N 	 1 	 million 89.6
29 	 22 	 PP/NP 	 1 	 cents with
29 	 28 	 N/N 	 1 	 cents 49
29 	 30 	 (NP\NP)/N 	 1 	 cents a
29 	 34 	 (S[dcl]\NP)/NP 	 2 	 cents earned <XU>
31 	 30 	 (NP\NP)/N 	 2 	 share a
33 	 34 	 (S[dcl]\NP)/NP 	 1 	 it earned
34 	 37 	 ((S\NP)\(S\NP))\NP 	 2 	 earned ago
36 	 35 	 NP[nb]/N 	 1 	 year a
36 	 37 	 ((S\NP)\(S\NP))\NP 	 3 	 year ago
<\s>
<s id="wsj_2341.36"> 15
0 	 1 	 (NP[nb]/N)\NP 	 2 	 Upjohn 's
3 	 1 	 (NP[nb]/N)\NP 	 1 	 drugs 's
3 	 2 	 N/N 	 1 	 drugs biggest-selling
3 	 4 	 (S[dcl]\NP)/NP 	 1 	 drugs are
5 	 4 	 (S[dcl]\NP)/NP 	 2 	 Xanax are
8 	 4 	 (S[dcl]\NP)/NP 	 2 	 tranquilizer are
8 	 7 	 NP[nb]/N 	 1 	 tranquilizer a
11 	 4 	 (S[dcl]\NP)/NP 	 2 	 Halcion are
14 	 4 	 (S[dcl]\NP)/NP 	 2 	 sedative are
14 	 13 	 NP[nb]/N 	 1 	 sedative a
<\s>
<s id="wsj_2341.37"> 28
0 	 1 	 (NP\NP)/NP 	 1 	 Sales of
0 	 4 	 (S[dcl]\NP)/(S[pt]\NP) 	 1 	 Sales have
0 	 6 	 S[pss]\NP 	 1 	 Sales hurt <XB>
3 	 1 	 (NP\NP)/NP 	 2 	 drugs of
3 	 2 	 NP[nb]/N 	 1 	 drugs both
5 	 4 	 (S[dcl]\NP)/(S[pt]\NP) 	 2 	 been have
6 	 5 	 (S[pt]\NP)/(S[pss]\NP) 	 2 	 hurt been
6 	 7 	 ((S\NP)\(S\NP))/NP 	 2 	 hurt by
10 	 7 	 ((S\NP)\(S\NP))/NP 	 3 	 laws by
10 	 8 	 N/N 	 1 	 laws new
10 	 9 	 N/N 	 1 	 laws state
10 	 11 	 (S[ng]\NP)/NP 	 1 	 laws restricting <XB>
13 	 11 	 (S[ng]\NP)/NP 	 2 	 prescriptions restricting
13 	 12 	 NP[nb]/N 	 1 	 prescriptions the
13 	 14 	 (NP\NP)/NP 	 1 	 prescriptions of
17 	 14 	 (NP\NP)/NP 	 2 	 medicines of
17 	 15 	 N/N 	 1 	 medicines certain
17 	 16 	 N/N 	 1 	 medicines tranquilizing
20 	 7 	 ((S\NP)\(S\NP))/NP 	 3 	 publicity by
20 	 19 	 N/N 	 1 	 publicity adverse
20 	 21 	 (NP\NP)/NP 	 1 	 publicity about
24 	 21 	 (NP\NP)/NP 	 2 	 use about
24 	 22 	 NP[nb]/N 	 1 	 use the
24 	 23 	 N/N 	 1 	 use excessive
24 	 25 	 (NP\NP)/NP 	 1 	 use of
27 	 25 	 (NP\NP)/NP 	 2 	 drugs of
27 	 26 	 NP[nb]/N 	 1 	 drugs the
<\s>
<s id="wsj_2341.38"> 47
3 	 2 	 NP[nb]/N 	 1 	 company the
3 	 4 	 (NP[nb]/N)\NP 	 2 	 company 's
6 	 4 	 (NP[nb]/N)\NP 	 1 	 drug 's
6 	 5 	 N/N 	 1 	 drug hair-growing
6 	 10 	 (S[dcl]\NP)/(S[ng]\NP) 	 1 	 drug is
6 	 11 	 S[ng]\NP 	 1 	 drug selling <XB>
8 	 10 	 (S[dcl]\NP)/(S[ng]\NP) 	 1 	 Rogaine is
8 	 11 	 S[ng]\NP 	 1 	 Rogaine selling <XB>
10 	 0 	 S/S 	 1 	 is Also
10 	 46 	 (S[dcl]\S[dcl])\NP 	 1 	 is said
11 	 10 	 (S[dcl]\NP)/(S[ng]\NP) 	 2 	 selling is
11 	 12 	 (S\NP)\(S\NP) 	 2 	 selling well
11 	 14 	 ((S\NP)\(S\NP))/NP 	 2 	 selling at
14 	 13 	 ((S\NP)\(S\NP))/((S\NP)\(S\NP)) 	 3 	 at --
16 	 14 	 ((S\NP)\(S\NP))/NP 	 3 	 $ at
16 	 15 	 N/N 	 1 	 $ about
16 	 19 	 (NP\NP)/NP 	 1 	 $ for
18 	 16 	 N/N[num] 	 1 	 million $
18 	 17 	 N/N 	 1 	 million 125
21 	 19 	 (NP\NP)/NP 	 2 	 year for
21 	 20 	 NP[nb]/N 	 1 	 year the
25 	 24 	 NP[nb]/N 	 1 	 company the
25 	 26 	 (NP[nb]/N)\NP 	 2 	 company 's
27 	 26 	 (NP[nb]/N)\NP 	 1 	 profit 's
27 	 28 	 (NP\NP)/NP 	 1 	 profit from
27 	 31 	 (S[dcl]\NP)/(S[pt]\NP) 	 1 	 profit has
27 	 33 	 S[pss]\NP 	 1 	 profit reduced <XB>
30 	 28 	 (NP\NP)/NP 	 2 	 drug from
30 	 29 	 NP[nb]/N 	 1 	 drug the
31 	 0 	 S/S 	 1 	 has Also
31 	 46 	 (S[dcl]\S[dcl])\NP 	 1 	 has said
32 	 31 	 (S[dcl]\NP)/(S[pt]\NP) 	 2 	 been has
33 	 32 	 (S[pt]\NP)/(S[pss]\NP) 	 2 	 reduced been
33 	 34 	 ((S\NP)\(S\NP))/NP 	 2 	 reduced by
35 	 36 	 (NP[nb]/N)\NP 	 2 	 Upjohn 's
41 	 34 	 ((S\NP)\(S\NP))/NP 	 3 	 campaigns by
41 	 36 	 (NP[nb]/N)\NP 	 1 	 campaigns 's
41 	 37 	 N/N 	 1 	 campaigns expensive
41 	 38 	 N/N 	 1 	 campaigns print
41 	 40 	 N/N 	 1 	 campaigns television
41 	 42 	 (NP\NP)/NP 	 1 	 campaigns for
43 	 42 	 (NP\NP)/NP 	 2 	 advertising for
45 	 46 	 (S[dcl]\S[dcl])\NP 	 2 	 analysts said
<\s>
<s id="wsj_2341.39"> 8
1 	 0 	 (S/S)/NP 	 2 	 Kalamazoo In
3 	 0 	 (S/S)/NP 	 2 	 Mich. In
5 	 6 	 (S[dcl]\NP)/NP 	 1 	 Upjohn declined
6 	 0 	 (S/S)/NP 	 1 	 declined In
7 	 6 	 (S[dcl]\NP)/NP 	 2 	 comment declined
<\s>
